klower legal Leaders Exchange Wolters Kluwer Legal & Regulatory
Description
The primary safety endpoint was blood glucose, because tesamorelin can reduce insulin sensitivity leading to hyperglycaemia
Behav Neurosci 122:368376
[DOI] [PMC free article] [PubMed] [Google Scholar] 42.Wang Y., Liang X., Andrikopoulos N., Zheng S., Li Y., Ke P.C
The MHRA position, summarised by Lynda Scammell (head of borderline products at the MHRA) and reported in The Guardian on 4 April 2026, is that products which are sold for human use or which carry medicinal claims fall inside the Human Medicines Regulations 2012, and that the MHRA is investigating UK clinics making such claims about unregulated peptide products
It's not just about avoiding triggers
